NeoGenomics, Inc. (NEO): Price and Financial Metrics
GET POWR RATINGS... FREE!
NEO POWR Grades
- NEO scores best on the Momentum dimension, with a Momentum rank ahead of 53.09% of US stocks.
- NEO's strongest trending metric is Sentiment; it's been moving down over the last 206 days.
- NEO ranks lowest in Sentiment; there it ranks in the 3rd percentile.
NEO Stock Summary
- The price/operating cash flow metric for Neogenomics Inc is higher than 99.01% of stocks in our set with a positive cash flow.
- With a year-over-year growth in debt of 281.19%, Neogenomics Inc's debt growth rate surpasses 95.72% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Neogenomics Inc is reporting a growth rate of -546.69%; that's higher than only 3.29% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Neogenomics Inc are INGN, CCMP, CLNE, BV, and VRM.
- NEO's SEC filings can be seen here. And to visit Neogenomics Inc's official web site, go to www.neogenomics.com.
NEO Price Target
For more insight on analysts targets of NEO, see our NEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $60.00 | Average Broker Recommendation | 1.29 (Strong Buy) |
NEO Stock Price Chart Interactive Chart >
NEO Price/Volume Stats
| Current price | $38.11 | 52-week high | $61.57 |
| Prev. close | $36.62 | 52-week low | $25.19 |
| Day low | $36.62 | Volume | 1,817,200 |
| Day high | $38.14 | Avg. volume | 995,344 |
| 50-day MA | $46.92 | Dividend yield | N/A |
| 200-day MA | $45.87 | Market Cap | 4.49B |
NeoGenomics, Inc. (NEO) Company Bio
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.
Latest NEO News From Around the Web
Below are the latest news stories about Neogenomics Inc that investors may wish to consider to help them evaluate NEO as an investment opportunity.
Zacks.com featured highlights include: HealthEquity, NeoGenomics, Howard Hughes Corp and StoneCoZacks.com featured highlights include: HealthEquity, NeoGenomics, Howard Hughes Corp and StoneCo |
3 Top Small-Cap Stocks to Buy Right NowThe broad market may struggle in the coming months to hold onto the remarkable gains it put up over the course of the past year. None of them are household names -- but that's the point. While President Joe Biden's infrastructure spending plan touches on a lot of things that haven't traditionally been considered infrastructure -- like child care and technological R&D -- it's still first and foremost a plan to repair and upgrade the nation's roads, bridges, waterways, and the like. |
NeoGenomics to acquire liquid biopsy firm InivataNeoGenomics (NEO) has agreed to acquire Inivata Ltd, a a liquid biopsy platform company headquartered in Cambridge, England.The acquisition follows a $25M minority equity investment by NeoGenomics in Inivata in May 2020, at which time NEO was granted a fixed price option to purchase the remainder of Inivata for $390M... |
NeoGenomics Snaps Up InivataNeoGenomics Inc. (NEO), which provides cancer-focused genetic testing and contract research, has agreed to acquire Inivata Limited. Inivata is a commercial-stage liquid biopsy platform provider. NeoGenomics had acquired a minority stake in Inivata in May 2020 for $25 million. At the time, NeoGenomics received an option to acquire the rest of the stake in Inivata for $390 million before the end of December 2021. NeoGenomics is funding this acquisition with cash on hand, coupled with an equity private placement of about $200 million. It expects the acquisition to simultaneously close with the private placement in June. |
NeoGenomics Exercises Option To Acquire Remaining Stake In Inivata For $390MNeoGenomics Inc (NASDAQ: NEO ) has agreed to acquire the remaining stake in Inivata Ltd, a commercial-stage liquid biopsy platform company headquartered in England. The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May last year, at which time NeoGenomics was granted a fixed price option … Full story available on Benzinga.com |
NEO Price Returns
| 1-mo | -23.07% |
| 3-mo | -36.36% |
| 6-mo | -11.52% |
| 1-year | 34.33% |
| 3-year | 238.76% |
| 5-year | 343.66% |
| YTD | -29.22% |
| 2020 | 84.07% |
| 2019 | 131.96% |
| 2018 | 42.33% |
| 2017 | 3.38% |
| 2016 | 8.89% |
Continue Researching NEO
Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...